uptake and photodynamic effect of porphyrins.
J Control Release 205:35–44
61. Lu M, Zhao X, Xing H, Xun Z, Zhu S, Lang L,
Yang T, Cai C, Wang D, Ding P (2018) Comparison of exosome-mimicking liposomes with
conventional liposomes for intracellular delivery of siRNA. Int J Pharm 550:100–113
62. Kaneti L, Bronshtein T, Malkah Dayan N,
Kovregina I, Letko Khait N, Lupu-Haber Y,
Fliman M, Schoen BW, Kaneti G, Machluf M
(2016) Nanoghosts as a novel natural nonviral
gene delivery platform safely targeting multiple
cancers. Nano Lett 16:1574–1582
63. Krishnamurthy S, Gnanasammandhan MK,
Xie C, Huang K, Cui MY, Chan JM (2016)
Monocyte cell membrane-derived nanoghosts
for targeted cancer therapy. Nanoscale
8:6981–6985
64. Lupu-Haber Y, Bronshtein T, ShalomLuxenburg H et al (2019) Pretreating mesenchymal stem cells with cancer conditionedmedia or proinflammatory cytokines changes
the tumor and immune targeting by nanoghosts derived from these cells. Adv Healthc
Mater 8:1801589. https://doi.org/10.1002/
adhm.201801589
65. Bronshtein T, Toledano N, Danino D,
Pollack S, Machluf M (2011) Cell derived liposomes expressing CCR5 as a new targeted
drug-delivery system for HIV infected cells. J
Control Release 151:139–148
66. Nakase I, Futaki S (2015) Combined treatment
with a pH-sensitive fusogenic peptide and cationic lipids achieves enhanced cytosolic delivery of exosomes. Sci Rep 5:10112
67. Lin Y, Wu J, Gu W, Huang Y, Tong Z,
Huang L, Tan J (2018) Exosome-liposome
hybrid nanoparticles deliver CRISPR/Cas9
system in MSCs. Adv Sci (Weinheim, BadenWurttemberg, Germany) 5:1700611
68. Sato YT, Umezaki K, Sawada S, Mukai S,
Sasaki Y, Harada N, Shiku H, Akiyoshi K
(2016) Engineering hybrid exosomes by membrane fusion with liposomes. Sci Rep 6:21933
69. Piffoux M, Silva AKA, Wilhelm C, Gazeau F,
Tareste D (2018) Modification of extracellular
vesicles by fusion with liposomes for the design
of personalized biogenic drug delivery systems.
ACS Nano 12:6830–6842
70. Kooijmans SAA, Fliervoet LAL, van der MR,
MHAM F, HFG H, en HPMP v B, Vader P,
Schiffelers RM (2016) PEGylated and targeted
extracellular vesicles display enhanced cell specificity and circulation time. J Control Release
224:77–85
71. Goh WJ, Zou S, Czarny B, Pastorin G (2018)
nCVTs: a hybrid smart tumour targeting platform. Nanoscale 10:6812–6819
72. Illes B, Hirschle P, Barnert S, Cauda V,
Wuttke S, Engelke H (2017) Exosome-coated
metal–organic framework nanoparticles: an
efficient drug delivery platform. Chem Mater
29:8042–8046
73. Fang RH, Hu C-MJ, Luk BT, Gao W, Copp
JA, Tai Y, O’Connor DE, Zhang L (2014)
Cancer cell membrane-coated nanoparticles
for anticancer vaccination and drug delivery.
Nano Lett 14:2181–2188
74. Jin J, Krishnamachary B, Barnett JD,
Chatterjee S, Chang D, Mironchik Y,
Wildes F, Jaffee EM, Nimmagadda S, Bhujwalla ZM (2019) Human cancer cell
membrane-coated biomimetic nanoparticles
reduce fibroblast-mediated invasion and metastasis and induce T-cells. ACS Appl Mater Interfaces 11:7850–7861
170
Yi-Hsuan Ou et al.
J Control Release 205:35–44
61. Lu M, Zhao X, Xing H, Xun Z, Zhu S, Lang L,
Yang T, Cai C, Wang D, Ding P (2018) Comparison of exosome-mimicking liposomes with
conventional liposomes for intracellular delivery of siRNA. Int J Pharm 550:100–113
62. Kaneti L, Bronshtein T, Malkah Dayan N,
Kovregina I, Letko Khait N, Lupu-Haber Y,
Fliman M, Schoen BW, Kaneti G, Machluf M
(2016) Nanoghosts as a novel natural nonviral
gene delivery platform safely targeting multiple
cancers. Nano Lett 16:1574–1582
63. Krishnamurthy S, Gnanasammandhan MK,
Xie C, Huang K, Cui MY, Chan JM (2016)
Monocyte cell membrane-derived nanoghosts
for targeted cancer therapy. Nanoscale
8:6981–6985
64. Lupu-Haber Y, Bronshtein T, ShalomLuxenburg H et al (2019) Pretreating mesenchymal stem cells with cancer conditionedmedia or proinflammatory cytokines changes
the tumor and immune targeting by nanoghosts derived from these cells. Adv Healthc
Mater 8:1801589. https://doi.org/10.1002/
adhm.201801589
65. Bronshtein T, Toledano N, Danino D,
Pollack S, Machluf M (2011) Cell derived liposomes expressing CCR5 as a new targeted
drug-delivery system for HIV infected cells. J
Control Release 151:139–148
66. Nakase I, Futaki S (2015) Combined treatment
with a pH-sensitive fusogenic peptide and cationic lipids achieves enhanced cytosolic delivery of exosomes. Sci Rep 5:10112
67. Lin Y, Wu J, Gu W, Huang Y, Tong Z,
Huang L, Tan J (2018) Exosome-liposome
hybrid nanoparticles deliver CRISPR/Cas9
system in MSCs. Adv Sci (Weinheim, BadenWurttemberg, Germany) 5:1700611
68. Sato YT, Umezaki K, Sawada S, Mukai S,
Sasaki Y, Harada N, Shiku H, Akiyoshi K
(2016) Engineering hybrid exosomes by membrane fusion with liposomes. Sci Rep 6:21933
69. Piffoux M, Silva AKA, Wilhelm C, Gazeau F,
Tareste D (2018) Modification of extracellular
vesicles by fusion with liposomes for the design
of personalized biogenic drug delivery systems.
ACS Nano 12:6830–6842
70. Kooijmans SAA, Fliervoet LAL, van der MR,
MHAM F, HFG H, en HPMP v B, Vader P,
Schiffelers RM (2016) PEGylated and targeted
extracellular vesicles display enhanced cell specificity and circulation time. J Control Release
224:77–85
71. Goh WJ, Zou S, Czarny B, Pastorin G (2018)
nCVTs: a hybrid smart tumour targeting platform. Nanoscale 10:6812–6819
72. Illes B, Hirschle P, Barnert S, Cauda V,
Wuttke S, Engelke H (2017) Exosome-coated
metal–organic framework nanoparticles: an
efficient drug delivery platform. Chem Mater
29:8042–8046
73. Fang RH, Hu C-MJ, Luk BT, Gao W, Copp
JA, Tai Y, O’Connor DE, Zhang L (2014)
Cancer cell membrane-coated nanoparticles
for anticancer vaccination and drug delivery.
Nano Lett 14:2181–2188
74. Jin J, Krishnamachary B, Barnett JD,
Chatterjee S, Chang D, Mironchik Y,
Wildes F, Jaffee EM, Nimmagadda S, Bhujwalla ZM (2019) Human cancer cell
membrane-coated biomimetic nanoparticles
reduce fibroblast-mediated invasion and metastasis and induce T-cells. ACS Appl Mater Interfaces 11:7850–7861
170
Yi-Hsuan Ou et al.